Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

FDA Inspection Authority Provisions In FDORA May Help Make 2023 A Happy New Year For Agency

January 6, 2023

Prevision Policy Clips | Narcan OTC Will Be Reviewed By FDA Advisory Committee: Broader Implications

January 6, 2023

Eylea Pediatric Use: FDA Asks Committee For Closer Look At Proposed Label For Infant Retinopathy; Agency May Want More Post-Treatment Monitoring

January 6, 2023

Advisory Committee Tracker: Another Unusual ODAC Set For February; COVID Vaccines, iPledge REMS Will Also Be Topics Early In 2023

January 5, 2023

Prevision Policy Clips | Seven Years’ War: Fabre-Kramer Submits NDA Amendment For Gepirone Seven Years After Dispute Resolution

January 5, 2023

Prevision Policy Clips | REMS Content & Format Final Guidance From FDA

January 4, 2023

Aduhelm Congressional Report Provides Anticlimactic Coda To FDA Controversy; Clarifying Use Of “Point/Counterpoint” Briefing Document May Be One Outcome

January 3, 2023

CMS New Technology Add-On Payment Applications For FY 2024 Include Five Bispecific Antibodies Among 20 Drug Candidates; Likely Rebound After Small Class Of 2023

January 3, 2023

Prevision Policy Clips | FDA Novel Therapeutics Approvals In 2022

January 3, 2023

Prevision Policy Clips | FDORA Set To Become Law

December 23, 2022

FDORA Clinical Trial Provisions Are Jumping Off Point For FDA Priority Under Califf: Diversity Is Main Political Theme; “Decentralized” And “Seamless” Guidances Will Be Key For Industry

December 22, 2022

“Platform Technologies” Pathway Will Be Important New FDA Tool In 2023; Sen. Burr’s Parting Gifts Include Stripping “Anti-Innovation” Amendments From FDA Year-End Package

December 22, 2022

Prevision Policy Clips | J&J, Perrigo Among Participants In Briefing With HHS Secretary On OTC Pediatric Cold & Flu Medicines

December 22, 2022

Accelerated Approval Reforms In FDORA Follow Senate Blueprint; Highlight of “Drugs & Biologics” Section Of Year-End Bill

December 21, 2022

FDORA Puts Cap On Big Year For FDA: User Fee Riders, PREVENT Pandemic Act Reforms Make Year End Omnibus; “Platform Technologies” Could Be One To Watch

December 21, 2022

Prevision Policy Clips | GSK Jemperli Rectal Cancer Indication Development Plan Will Be Focus Of Unusual ODAC

December 21, 2022

ICER Panel Skeptical Of Astellas’ Novel NK3 For Menopause Symptoms; Lack Of Peer Reviewed Data Raises Concerns

December 20, 2022

Prevision Policy Clips | FDA Reforms Ready To Move In Lame Duck: “FDORA”

December 20, 2022

FDA Gene Editing Safety Workshop: Targeted Approaches To Screen For Off-Target Effects?

December 19, 2022

Prevision Policy Clips | Madrigal Pharma To Pursue Accelerated Approval For NASH Drug In First Half Of 2023

December 19, 2022

Cytokinetics OM For Heart Failure Has Uncertain Future: Large Heart Failure Trial Is Not “Substantial Evidence” On Its Own, FDA Committee Agrees

December 16, 2022

Prevision Policy Clips | FDA’s VRBPAC To Meet Jan. 26 To Discuss “Future Vaccination Regimens” For COVID, Still Virtual

December 16, 2022

Sentinel Pregnancy Data Work Under PDUFA VII May Be Key Step In Moving FDA Active Surveillance System Beyond Supporting Role; EHR Integration Is Longer-Term Opportunity

December 15, 2022

OCE’s “Project Renewal” Concludes First Label Update – After Four Years: Genentech Xeloda Has Eight New And Revised Indications

December 15, 2022

Prevision Policy Clips | CMS Delays Initial Decision On Updating Beta Amyloid PET Scan Coverage Policy

December 15, 2022
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy